The future of clinical trials in secondary prevention after acute coronary syndromes

European Heart Journal

Volumn 32, Issue 13, 2011, Pages 1583-1589

  Bueno, Hctor ^a   Armstrong, Paul W ^b   Buxton, Martin J ^c   Danchin, Nicolas ^d   Lubsen, Jacobus ^e   Roland, Edmond ^f   Verheugt, Freek W ^g   Zalewski, Andrew ^h   Jackson, Neville ⁱ   Komajda, Michel ^j   Steg, Ph Gabriel ^k  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b UNIVERSITY OF ALBERTA   (Canada)

^c BRUNEL UNIVERSITY   (United Kingdom)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f AFSSAPS   (France)

^g ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^h Pfizer ^*

ⁱ PFIZER INC   (United States)

^j PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^k INSERM   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ACUTE CORONARY SYNDROME; ARTICLE; COST BENEFIT ANALYSIS; ECONOMIC ASPECT; EVIDENCE BASED MEDICINE; HUMAN; PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICAL ANALYSIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT PLANNING;

ACUTE CORONARY SYNDROME; COSTS AND COST ANALYSIS; HUMANS; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGISTRIES; RESEARCH DESIGN; RISK ASSESSMENT; SAMPLE SIZE; SECONDARY PREVENTION; STATISTICS AS TOPIC; TREATMENT OUTCOME;

EID: 79960017543     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehq388     Document Type: Article

References (20)

1. Tricoci P, Allen JM, Kramer JM, Califf RM, Smith SC Jr. Scientific evidence underlying the ACC/AHA clinical practice guidelines. J Am Med Assoc 2009;301: 831-841.
2. US Department of Health and Human Services. Food and Drug Administration. FDA. Critical Path Opportunities Report and List. Available at http://www.fda.gov/oc/initiatives/criticalpath/2006.
3. PricewaterhouseCoopers. Pharma 2020: Virtual R&D\Which path will you take?; 2007: 20. http://www.pwc.com/en-GX/gx/pharma-life-sciences/pdf/ pharma2020-virtualrd-final2.pdf.
4. Steg PG, Lopez-Sendon J, Lopez de Sa E, Goodman SG, Gore JM, Anderson FA Jr, Himbert D, Allegrone J, Van de Werf F. External validity of clinical trials in acute myocardial infarction. Arch Intern Med 2007;167:68-73. (Pubitemid 46072409)
5. Lee PY, Alexander KP, Hammill BG, Pasquali SK, Peterson ED. Representation of elderly persons and women in published randomized trials of acute coronary syndromes. J Am Med Assoc 2001;286:708-713. (Pubitemid 33010364)
6. Califf RM. Clinical research sites - the underappreciated component of the clinical research system. J Am Med Assoc 2009;302:2025-2027.
7. Glickman SW, McHutchison JG, Peterson ED, Cairns CB, Harrington RA, Califf RM, Schulman KA. Ethical and scientific implications of the globalization of clinical research. N Engl J Med 2009;360:816-823.
8. Mehta C, Gao P, Bhatt DL, Harrington RA, Skerjanec S, Ware JH. Optimizing trial design: sequential, adaptive, and enrichment strategies. Circulation 2009;119: 597-605.
9. Freemantle N, Calvert M, Wood J, Eastaugh J, Griffin C. Composite outcomes in randomized trials: greater precision but with greater uncertainty? J Am Med Assoc 2003;289:2554-2559. (Pubitemid 37430157)
10. Thygesen K, Alpert JS, White HD. Universal definition of myocardial infarction. Eur Heart J 2007;28:2525-2538. (Pubitemid 47616190)
11. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007;115:2344-2351. (Pubitemid 46685903)
12. Rao SV, Eikelboom J, Steg PG, Lincoff AM, Weintraub WS, Bassand JP, Rao AK, Gibson CM, Petersen JL, Mehran R, Manoukian SV, Charnigo R, Lee KL, Moscucci M, Harrington RA. Standardized reporting of bleeding complications for clinical investigations in acute coronary syndromes: a proposal from the academic bleeding consensus (ABC) multidisciplinary working group. Am Heart J 2009;158:881-886 e881.
13. Cleland JGF. How to assess new treatments for the management of heart failure: composite scoring systems to assess the patients' clinical journey. Eur J Heart Fail 2002;4:243-247. (Pubitemid 35190346)
14. European Medicines Agency. Guideline on the Evaluation of Medicinal Products for Cardiovascular Disease Prevention. London; 2007, p.6. http://www.emea.europa.eu/pdfs/human/ewp/31189007en.pdf.
15. McDonough PG. Clinically relevant differences and 'Biocreep'. Fertil Steril 2004;81: 1424-1426.
16. Hansson L, Hedner T, Dahlof B. Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective Randomized Open Blinded End-Point. Blood Press 1992;1:113-119.
17. European Medicines Agency. CPMP/EWP/908/99. Points to Consider on the Multiplicity Issues in Clinical Trials. London; 2002. p.10. http://www.emea. europa.eu/pdfs/human/ewp/090899en.pdf.
18. Califf RM. Clinical trials bureaucracy: unintended consequences of well-intentioned policy. Clin Trials 2006;3:496-502.
19. Greiner W, Weijnen T, Nieuwenhuizen M, Oppe S, Badia X, Busschbach J, Buxton M, Dolan P, Krabbe P, Ohinmaa A, Parkin D, Roset M, Sintonen H, Tsuchiya A, Charro F. A single European currency for EQ-5D health states. Eur J Health Econ 2003;4:222-231.
20. Gitt AK, Bueno H, Danchin N, Fox K, Kearney P, Maggioni AP, Opolski G, Seabra-Gomes R, Weidinger F. The role of cardiac registries in evidence-based medicine. Eur Heart J 2010;31:525-529.